.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 7,541,384

« Back to Dashboard

Details for Patent: 7,541,384

Title:Mesalamine suppository
Abstract: The present invention relates to a mesalamine rectal suppository designed to provide improved comfort of use. One embodiment of the invention is a mesalamine rectal suppository containing mesalamine and one or more pharmaceutically acceptable excipients, wherein the drug load of the suppository ranges from 35% to 50%. Another embodiment of the invention is a mesalamine rectal suppository containing from about 850 to about 1150 mg mesalamine and one or more pharmaceutically acceptable excipients, wherein the total weight of the suppository ranges from about 2250 to about 2700 mg. Yet another embodiment of the invention is a mesalamine rectal suppository comprising mesalamine having a tap density ranging from about 600 to about 800 g/L (as measured by USP <616>) and a hard fat having an ascending melting point of 32 to 35.5.degree. C. Methods of preparing and methods of treatment with mesalamine suppositories are also provided. The invention further provides a method of determining a dissolution parameter (such as dissolution rate) of a mesalamine rectal suppository, such as a 1 g mesalamine suppository, by measuring its dissolution with USP Apparatus #2 at 40.degree. C. and a paddle rotation speed of 125 rpm in 0.2 M phosphate buffer at a pH of 7.5.
Inventor(s): Gauthier; Carl (Quebec, CA), Dumoulin; Yves (Quebec, CA), Powell; David (Loudon, TN)
Assignee: Axcan Pharma Inc. (Mont-St-Hilaire, Quebec, CA)
Filing Date:Oct 03, 2008
Application Number:12/245,648
Claims:1. A mesalamine rectal suppository comprising from about 850 to about 1150 mg of mesalamine and a fatty base, wherein the mesalamine has a tap density ranging from about 600 to about 800 g/L (as measured by USP <616>), the drug load of the suppository ranges from 35% to 46%, and the suppository releases at least 75% by weight of the mesalamine within 2 hours of dissolution as measured with USP Apparatus #2 at 40.degree. C., a paddle rotation speed of 125 rpm, and 3 sinker turns in 0.2 M phosphate buffer at a pH of 7.5.

2. The mesalamine suppository of claim 1, wherein the amount of mesalamine ranges from about 950 to about 1050 mg.

3. The mesalamine suppository of claim 1, wherein the fatty base is hard fat.

4. The mesalamine suppository of claim 1, wherein the fatty base has an ascending melting point ranging from 32 to 33.5.degree. C.

5. The mesalamine suppository of claim 1, wherein the fatty base has an ascending melting point from 33 to 35.5.degree. C.

6. The mesalamine suppository of claim 4, the base is hard fat.

7. The mesalamine suppository of claim 5, the fatty base is hard fat.

8. The mesalamine suppository of claim 1, wherein the drug load ranges from about 39 to about 45%.

9. The mesalamine suppository of claim 8, wherein the drug load ranges from about 41 to about 43%.

10. The mesalamine suppository of claim 1, wherein the suppository releases at least 80% by weight of the mesalamine within 2 hours of dissolution as measured with USP Apparatus #2 at 40.degree. C., a paddle rotation speed of 125 rpm, and 3 sinker turns in 0.2 M phosphate buffer at a pH of 7.5.

11. The mesalamine suppository of claim 1, wherein the suppository releases at least 80% by weight of the mesalamine within 1 hour of dissolution as measured with USP Apparatus #2 at 40.degree. C., a paddle rotation speed of 125 rpm, and 3 sinker turns in 0.2 M phosphate buffer at a pH of 7.5.

12. The mesalamine suppository of claim 1, wherein the suppository releases at least 90% by weight of the mesalamine within 30 minutes of dissolution as measured with USP Apparatus #2 at 40.degree. C., a paddle rotation speed of 125 rpm, and 3 sinker turns in 0.2 M phosphate buffer at a pH of 7.5.

13. A method of treating active ulcerative proctitis in a patient in need thereof comprising administering the mesalamine rectal suppository of claim 1 to the patient.

14. The method of claim 13, wherein the mesalamine rectal suppository is administered once a day.

15. The method of claim 14, wherein the mesalamine rectal suppository is administered once a day at bedtime.

16. The mesalamine suppository of claim 1, wherein the suppository is a moulded suppository.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc